MarketCap
Facebook
X
TelegramFive Prime Therapeutics, Inc. Income Statement 2020-2011 | FPRX
Brief overview of income trends at Five Prime Therapeutics, Inc.
The comparison covers a five-year financial horizon. Revenue at Five Prime Therapeutics, Inc. moved from 380 million dollars in 2015 to 13.2 million dollars in 2020. The five-year change reached −96.5%, while CAGR stood at −48.9%. The negative rate indicates weakening core operations.
EBITDA changed from 289 million dollars to −87 million dollars (−130.1%). Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from 76% to −660%. A lower EBITDA share weakens the quality of the result.
Across the five years, the net result shifted from 250 million dollars to −84.3 million dollars. A positive result was not sustained and the period ended with a loss.
Over the period, capitalization shifted from $923 million to $616 million (−33.2%). A large part of future progress may already be reflected in the valuation.
Conclusion
The financial trajectory is weak and requires a cautious interpretation. The overall view is constrained by a weaker market valuation, limited revenue growth and limited operating profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Five Prime Therapeutics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
616 M | 169 M | 384 M | 584 M | 1.19 B | 923 M | 549 M | 82.5 M | - | - |
Shares |
36.8 M | 35 M | 34 M | 27.9 M | 27 M | 25.7 M | 20.9 M | 5.52 M | - | - |
Net Income |
-84.3 M | -137 M | -140 M | -150 M | -65.7 M | 250 M | -37.4 M | -28.9 M | -27.6 M | 19.7 M |
Revenue |
13.2 M | 14.9 M | 49.9 M | 39.5 M | 30.7 M | 380 M | 19.2 M | 13.8 M | 9.98 M | 64.9 M |
EBITDA |
-87 M | -137 M | -141 M | -149 M | -97.5 M | 289 M | -36 M | -27.7 M | -26.2 M | 21.3 M |
Operating Expenses |
106 M | 157 M | 196 M | 191 M | 130 M | 92.8 M | 56.8 M | 43.2 M | 37.8 M | 45.3 M |
General and Administrative Expenses |
40.6 M | 42.7 M | 39.7 M | 40 M | 35.8 M | 22.6 M | 13.6 M | 10.4 M | 9.01 M | 11.2 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Five Prime Therapeutics, Inc. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
